Effective stakeholder analysis and engagement: a vital strategy for enhanced pharmacovigilance systems in sub-Saharan Africa
Babafunso A. Adenuga, Anastasia Aluvilu, Oluwaseun O. Olafusi, Dan Kibuule
References
1. Missonier S, Loufrani-Fedida S. Stakeholder analysis and engagement in projects: From stakeholder relational perspective to stakeholder relational ontology. Int J Proj Manag. 2014;32(7):1108-22. doi: 10.1016/j.ijproman.2014.02.010.
2. Adenuga BA, Kibuule D, Bamitale KDS, Rennie TW. Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study. Res Soc Adm Pharm. 2019. doi: 10.1016/j.sapharm.2019.11.010.
3. Adenuga BA, Kibuule D, Rennie TW. Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia. Basic Clin Pharmacol Toxicol. 2020;126(3):247-53. doi: 10.1111/bcpt.13325.
4. Inácio P, Cavaco A, Allan E, Airaksinen M. Key pharmacovigilance stakeholders’ experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union. Public Health. 2018;155:119-28. doi: 10.1016/j.puhe.2017.11.023.
5. Pawinski RA, Lalloo UG. Multisectoral responses to HIV/AIDS: Applying research to policy and practice. Am J Public Health. 2006;96(7):1189-91. doi: 10.2105/AJPH.2004.060897.
6. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Saf. 2017;40(10):855-69. doi: 10.1007/s40264-017-0572-8.
7. Varvasovszky Z, Brugha R. A stakeholder analysis Guidelines. Health Policy Plan. 2000;15(3):338-45. doi:10.1093/heapol/15.3.338.
Submitted date:
04/02/2020
Reviewed date:
04/08/2020
Accepted date:
04/09/2020
Publication date:
04/09/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email